Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Phoenix Trial: Cemiplimab for Localized dMMR Colon Cancer
NCT05961709Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2024
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in colon cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Endoscopic Complete Response at 6 months and Incidence of Adverse Events. Started May 2024; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05961709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961709.